Telix Pharmaceuticals reported first-half 2026 revenue of $477 million [3] during a virtual investor call held this month.
The results signal strong commercial momentum for the company as it expands its precision-medicine pipeline and updates its financial outlook for the year.
Telix said its revenue grew 22 percent [5] year-over-year for the period ending June 30, 2026 [6]. The company also disclosed an EBITDA of $52 million [4] for the first half of the year.
Based on these results, the company provided updated guidance for the remainder of the year. Telix now projects full-year 2026 revenue between $950 million and $970 million [1]. The company also set its research and development guidance for 2026 at between $230 million and $270 million [2].
The earnings call featured the company's Managing Director and Group CEO, who discussed the firm's late-stage pipeline and regulatory progress. The company aims to use the increased R&D investment to advance its precision-medicine offerings.
Telix is listed on both the ASX and NASDAQ under the ticker TLX. The financial period covered in the presentation concluded on June 30 [6], and the subsequent investor call served as the primary vehicle for disclosing these performance metrics to the market.
“Telix reported first-half 2026 revenue of $477 million”
The upward revision of revenue guidance suggests that Telix is successfully scaling its commercial operations. By allocating up to $270 million toward research and development, the company is prioritizing long-term pipeline growth over immediate profit maximization, a common strategy for biotech firms seeking to dominate niche precision-medicine markets.
